CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer

BackgroundGamabufotalin (CS-6), a bufadienolide derived from Chansu, has been reported to exhibit anti-tumor effects in various cancers, including glioblastoma, nonsmall cell lung cancer, and breast cancer. However,its role in colorectal cancer (CRC) remains unexplored.ObjectiveOur study aimed to ev...

Full description

Saved in:
Bibliographic Details
Main Authors: Yitong Gong, Menghan Dong, Xiaofei Feng, Naiyu Zhang, Xuehui Cui, Liushuyue Wang, Qi Qi, Chiu-fai Kuok, Qingling Jiang, Sixue Bi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1568339/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849312316658548736
author Yitong Gong
Yitong Gong
Menghan Dong
Xiaofei Feng
Xiaofei Feng
Naiyu Zhang
Xuehui Cui
Liushuyue Wang
Qi Qi
Chiu-fai Kuok
Qingling Jiang
Sixue Bi
author_facet Yitong Gong
Yitong Gong
Menghan Dong
Xiaofei Feng
Xiaofei Feng
Naiyu Zhang
Xuehui Cui
Liushuyue Wang
Qi Qi
Chiu-fai Kuok
Qingling Jiang
Sixue Bi
author_sort Yitong Gong
collection DOAJ
description BackgroundGamabufotalin (CS-6), a bufadienolide derived from Chansu, has been reported to exhibit anti-tumor effects in various cancers, including glioblastoma, nonsmall cell lung cancer, and breast cancer. However,its role in colorectal cancer (CRC) remains unexplored.ObjectiveOur study aimed to evaluate the inhibition of CS-6 to CRC cells by cell viability assay, colony formation assay, comet assay, and cell cycle analysis firstly. And its molecular mechanism was studied by immunofluorescence (IF) assay, western blot (WB) assay, siRNA transfection, protein-protein interaction (PPI) network and co-immunoprecipitation (Co-IP) assay. Finally, the in vivo antitumor assessments of CS-6 on colorectal cancer was validated through an transplant colorectal cancer model.ResultsCS-6 treatment significantly inhibited CRC SW620 and DLD1 cell viability and colony formation in vitro. Furthermore, CS-6 treatment-induced DNA damage and cell cycle arrest in SW620 and DLD1 cells. The western blot assay revealed that CS-6 treatment upregulated p62 expression. Knockdown of p62 in this study significantly alleviated CS-6-induced DNA damage and the downregulation of cyclin expression in SW620 and DLD1 cells. Additionally, the results indicated increased expression of microtubuleassociated protein I/II light chain 3II (LC3II) and reduced binding between B-cell lymphoma-2 (Bcl2) and beclin-1, suggesting that CS-6 treatment activated early-stage autophagy in CRC cells. However, inhibition of latestage autophagy and autophagy-related protein 5 (ATG5) with chloroquine and si-ATG5, respectively, further indicated that CS-6-induced autophagy defects led to p62 accumulation, exacerbated cell proliferation inhibition, and aggravated DNA damage. Intraperitoneal injection with CS-6 inhibited tumor growth in nude mice with colorectal cancer, and promoted the protein expression of phosphorylated H2A histone family member X (γH2AX), p62, phosphorylated Ataxia-telangiectasia mutated kinase (p-ATM) and LC3 I/II.ConclusionThis study suggests that CS-6 may exert its anti-tumor effects in CRC by inducing autophagy defects, resulting in p62 accumulation and DNA damage in vitro and in vivo.
format Article
id doaj-art-1603cfaa65bb42b2907992a0e64d012e
institution Kabale University
issn 1663-9812
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-1603cfaa65bb42b2907992a0e64d012e2025-08-20T03:53:07ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15683391568339CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancerYitong Gong0Yitong Gong1Menghan Dong2Xiaofei Feng3Xiaofei Feng4Naiyu Zhang5Xuehui Cui6Liushuyue Wang7Qi Qi8Chiu-fai Kuok9Qingling Jiang10Sixue Bi11Featured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaSchool of Humanities, Ludong University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaYantai Affiliated Hospital of Binzhou Medical University, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaFaculty of Health Sciences and Sports, Macao Polytechnic University, Macao, SAR ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaFeatured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong, ChinaBackgroundGamabufotalin (CS-6), a bufadienolide derived from Chansu, has been reported to exhibit anti-tumor effects in various cancers, including glioblastoma, nonsmall cell lung cancer, and breast cancer. However,its role in colorectal cancer (CRC) remains unexplored.ObjectiveOur study aimed to evaluate the inhibition of CS-6 to CRC cells by cell viability assay, colony formation assay, comet assay, and cell cycle analysis firstly. And its molecular mechanism was studied by immunofluorescence (IF) assay, western blot (WB) assay, siRNA transfection, protein-protein interaction (PPI) network and co-immunoprecipitation (Co-IP) assay. Finally, the in vivo antitumor assessments of CS-6 on colorectal cancer was validated through an transplant colorectal cancer model.ResultsCS-6 treatment significantly inhibited CRC SW620 and DLD1 cell viability and colony formation in vitro. Furthermore, CS-6 treatment-induced DNA damage and cell cycle arrest in SW620 and DLD1 cells. The western blot assay revealed that CS-6 treatment upregulated p62 expression. Knockdown of p62 in this study significantly alleviated CS-6-induced DNA damage and the downregulation of cyclin expression in SW620 and DLD1 cells. Additionally, the results indicated increased expression of microtubuleassociated protein I/II light chain 3II (LC3II) and reduced binding between B-cell lymphoma-2 (Bcl2) and beclin-1, suggesting that CS-6 treatment activated early-stage autophagy in CRC cells. However, inhibition of latestage autophagy and autophagy-related protein 5 (ATG5) with chloroquine and si-ATG5, respectively, further indicated that CS-6-induced autophagy defects led to p62 accumulation, exacerbated cell proliferation inhibition, and aggravated DNA damage. Intraperitoneal injection with CS-6 inhibited tumor growth in nude mice with colorectal cancer, and promoted the protein expression of phosphorylated H2A histone family member X (γH2AX), p62, phosphorylated Ataxia-telangiectasia mutated kinase (p-ATM) and LC3 I/II.ConclusionThis study suggests that CS-6 may exert its anti-tumor effects in CRC by inducing autophagy defects, resulting in p62 accumulation and DNA damage in vitro and in vivo.https://www.frontiersin.org/articles/10.3389/fphar.2025.1568339/fullgamabufotalin (CS-6)colorectal cancer (CRC)DNA damagep62autophagy
spellingShingle Yitong Gong
Yitong Gong
Menghan Dong
Xiaofei Feng
Xiaofei Feng
Naiyu Zhang
Xuehui Cui
Liushuyue Wang
Qi Qi
Chiu-fai Kuok
Qingling Jiang
Sixue Bi
CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer
Frontiers in Pharmacology
gamabufotalin (CS-6)
colorectal cancer (CRC)
DNA damage
p62
autophagy
title CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer
title_full CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer
title_fullStr CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer
title_full_unstemmed CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer
title_short CS-6-induced p62 accumulation exacerbates DNA damage in colorectal cancer
title_sort cs 6 induced p62 accumulation exacerbates dna damage in colorectal cancer
topic gamabufotalin (CS-6)
colorectal cancer (CRC)
DNA damage
p62
autophagy
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1568339/full
work_keys_str_mv AT yitonggong cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT yitonggong cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT menghandong cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT xiaofeifeng cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT xiaofeifeng cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT naiyuzhang cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT xuehuicui cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT liushuyuewang cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT qiqi cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT chiufaikuok cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT qinglingjiang cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer
AT sixuebi cs6inducedp62accumulationexacerbatesdnadamageincolorectalcancer